MINI FUTURE SHORT - NOVO-NORDISK B | Market Closed - Boerse Frankfurt Warrants 15:21:22 27/06/2024 BST | ||
| 1.2 EUR | +12.15% |
|
| Current month | -45.45% | ||
| 1 month | -48.05% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
NOVO NORDISK A/S
Latest news about NOVO NORDISK A/S
More news
| Date | Price | Change |
|---|---|---|
| 27/06/24 | 1.2 | +12.15% |
| 26/06/24 | 1.07 | +10.31% |
| 25/06/24 | 0.97 | -30.71% |
| 24/06/24 | 1.4 | 0.00% |
| 21/06/24 | 1.4 | -0.71% |
Real-time Boerse Frankfurt Warrants
Last update June 27, 2024 at 03:21 pm
More quotesStatic data
| Product type | Certificat Turbo Stop Loss |
|---|---|
| Buy / Sell | PUT |
| Underlying | NOVO NORDISK A/S |
| Issuer | 
BNP Paribas
|
| WKN | PC28XZ |
| ISIN | DE000PC28XZ9 |
| Date issued | 12/01/2024 |
| Strike | 1,093 kr |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 4.83 € |
| Emission volume | N/A |
| Settlement | règlement en espèces |
| Currency | EUR |
Technical Indicators
| Highest since issue | 5.31 € |
|---|---|
| Lowest since issue | 0.92 € |
Company Profile
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- diabetes and obesity treatment products (92.6%);
- rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc.
Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Sector
-
Consensus: Novo Nordisk A/S
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
26
Last Close Price
1,003
DKK
Average target price
937.9
DKK
Spread / Average Target
-6.45%
- Stock Market
- Certificates
- Certificat
